Participants: Prefrail older adults
Dosage: 50 mg/day of losartan for at least 8 weeks

Losartan, a common blood pressure medication, increases the survival rate of mice and improves the metabolic outlook of pre-frail older adults. 

Principal Investigator of the study, Dr. Peter M. Abadir (image: jhu.edu).

Aging &amp; Longevity

Participants: Older adults (ages 60 to 80) with mild cognitive impairment 
Dosage: 320 mg/day of anthocyanin capsules for 24 weeks

Anthocyanin, a compound found in berries, reduces inflammation and heart disease markers in older adults at risk for dementia.  

Lead author of the study, Dr. Miguel Germán Borda (image: noticias.cun.es).

Cardiovascular

Peter Fedichev’s Physics-Based Approach to Aging: A New Longevity Framework

Peter Fedichev describes aging as a three-variable system of stress (from physical, psychological, or molecular stressors), noise (small random biological fluctuations), and damage (cumulative wear-and-tear).

Peter Fedichev has proposed a physics-based framework for aging, encompassing stress, noise (small random biological fluctuations), and damage (cumulative wear-and-tear).

Participants: Sedentary older adults 
Dosage: 6 mg/week of rapamycin

In older adults, the FDA-approved drug rapamycin, associated with prolonging lifespan, blunts improvements in physical performance.

Skin &amp; Muscle

Model: C57BL/6 mice
Dosage: 500 mg/kg/day of SRN-901 via oral gavage for six days per week starting at 18 months of age; 14.4 ppm of rapamycin mixed in food starting at 18 months of age; 300 mg/kg/day of NMN via oral gavage for six days per week starting at 18 months of age; and 300 mg/kg/day of NR via oral gavage for six days per week starting at 18 months of age

Seragon Publishes Record-Breaking SRN-901 Longevity Data, Demonstrating 33% Lifespan Extension in Mice

In a newly published mouse study, SRN-901 extended remaining lifespan by 33%, slowed frailty progression, and lowered tumor incidence.

Seragon’s SRN-901 extended the remaining lifespan of adult mice by 33%, attenuated frailty progression by 70%, and reduced tumor incidence by 30.53%, according to a newly published preclinical study.

Search Result: Inflammation

New Johns Hopkins Study: FDA-Approved Losartan May Extend Lifespan

Anthocyanin Supplement Shows Anti-Inflammatory and Heart Health Benefits in New Study

Peter Fedichev’s Physics-Based Approach to Aging: A New Longevity Framework

Rapamycin and Exercise: New Study Finds Potential Performance Decline

Seragon Publishes Record-Breaking SRN-901 Longevity Data, Demonstrating 33% Lifespan Extension in Mice